| Status: Excluded due to NICE appraisal | |
Product meets AWMSG criteria due to NICE appraisal TA963: Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
|
Medicine details |
|
| Medicine name | dostarlimab (Jemperli®) |
| Formulation | 500 mg concentrate for solution for infusion |
| Reference number | 4865 |
| Indication | For the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen. |
| Company | GlaxoSmithKline UK |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/03/2023 |
| NICE guidance | |